Bitterroot Bio is excited to join academic, industry, regulatory, and cardiovascular patient representatives at the CVCT Forum this week in Washington, D.C.! #CVCTForum #BitterrootBio
About us
Harnessing the power of immunotherapy to develop and deliver transformative medicines for patients with cardiovascular disease
- Website
-
www.bitterrootbio.com
External link for Bitterroot Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Palo Alto, California
- Type
- Privately Held
- Founded
- 2021
Locations
-
Primary
3160 Porter Dr
Palo Alto, California 94304, US
Employees at Bitterroot Bio
-
Georgette Verdin
Chief People Officer - Passionate about leveraging culture and talent to realize business results
-
Sharline C.
-
Will Krause
Vice President Finance & Corporate Development
-
Cheralyn (Cher) McClurg Crokaerts
Executive Assistant/Executive Operations Manager| Operations, Executive Support
Updates
-
Bitterroot Bio will be at Evercore’s HealthCONx Conference on Dec. 3rd in Coral Gables. We are looking forward to connecting with industry leaders to help drive the future of cardiovascular care forward. #HealthCONx #HealthcareInnovation
-
We’re grateful to our team and our partners for their dedication and support as we advance our clinical studies in service of people suffering from atherosclerosis and cardiovascular disease. Wishing you a Thanksgiving holiday filled with gratitude. Happy Thanksgiving! 🦃🍁 #WeAreBitterroot
-
🌟 Transforming Science, and Evolving Culture 🌟 In mid-October, our team came together for an offsite to continue unpacking the groundbreaking science we are advancing. We also took some time to appreciate the intricacies of non-linear drug development, while building cultural bridges that will help make us a stronger, more connected team. From discussions with scientific luminaries to team-building exercises under the sun, we shared insights and challenges and spent time defining each of our behavioral values. Moments like these remind us that evolving as an organization isn’t just about advancing science—it’s about cultivating the culture that drives that innovation forward. Together, we’re shaping the culture and the science of Bitterroot Bio -- blending cutting-edge research with a collaborative spirit. #Innovation #TeamCulture #ScientificBreakthroughs #Collaboration #Leadership
-
Our team had the privilege of meeting last week with our incredible Clinical and Scientific Advisory Board members, both in-person and virtually, while we were attending the American Heart Association Scientific Sessions. Bitterroot is grateful for their wonderful insights and guidance, and we appreciate our advisory board members shared commitment to developing innovative cardio-immunology therapies for patients with heart disease.💡❤️ Christie Ballantyne MD, Marc Bonaca, Sandy Ferber Brine, Izzy Charo, Robert A. Harrington, Nicholas Leeper, Klaus Ley,Douglas Mann, Kathryn Moore, Matthias Nahrendorf, Daniel Rader, Kristy Red-Horse, Fil Swirski, Jonathan Weinsaft #SiddJaiswal #PaulRidker #IrvWeissman #Innovation #ScienceInAction #AHAConference #Gratitude #AdvisoryBoard #CardiovascularDisease #HopeForPatients #BitterrootBio
-
Our company leaders will be participating at the upcoming Jefferies London Healthcare Conference on November 20th and 21st. Looking forward to joining global healthcare leaders at one of the largest healthcare-dedicated conferences in Europe! #JefferiesHealthcare #BitterrootBio
-
We have completed enrollment in our Phase 1 study of BRB-002 in healthy volunteers. Topline findings are expected in early 2025, and we are excited to begin our Phase 2 proof-of-concept trial in patients with atherosclerosis in 2025. A huge thanks to our participants, teams, and partners for making this possible! Learn more by reading our press release here: https://lnkd.in/efuUETTb #BitterrootBio #NucleusNetwork #Novotech #360biolabs #BRB002 #heartdisease #cardiovascular #drugdevelopment
-
It is always a gift to hear an extraordinary leader share the motivation and focus it takes to drive success. Bitterroot Bio’s CEO, Pavan Cheruvu, shared his inspiring journey, with a learned and critical focus on talent and culture, on the Biotech 2050 podcast. What struck us the most is Pavan’s deep sense of responsibility, and keeping a keen eye on the north star of what we are working to accomplish. Now more than ever, it’s important for us to listen to leaders who remind us that with the right blend of scientific assets, mission driven team, supportive investors and a positive and dynamic company culture we have the opportunity to transform lives in life sciences. Listen here: https://lnkd.in/gp9M_BNZ #CardioImmunology #HeartHealth #BitterrootBio #Innovation #Leadership
-
A heartfelt thank you to the American Heart Association for their unwavering commitment to advancing research and advocacy in cardiovascular health. It’s an honor to be part of the Bay Area Legacy Circle—a community that not only cares deeply about the future of CVD treatment and prevention but actively supports it. With World Heart Day approaching on September 29th, it’s a perfect reminder of the power of community, collaboration, and shared purpose in tackling cardiovascular disease. We are grateful to be part of a community making a difference in the future of CVD.💙 #WorldHeartDay #ThankYouAHA #CVDCommunity #BayAreaLegacyCircle
-
Bitterroot Bio reposted this
Honored to represent Bitterroot Bio as I joined colleagues from across biotech at the Mass General World Medical Innovation Forum for a terrific panel discussion about the impact of metabolic therapies on cardiovascular and neurologic diseases. Thank you Patrick Ellinor and Jason Zemansky for moderating a wonderful conversation. The panel can be replayed at https://lnkd.in/eXvzEPsf online. #wmif #bitterrootbio #metabolism #heartdisease #atherosclerosis #drugdevelopment